The Rubin lab approach to cancer research has grown in parallel with the rapid expansion of bioinformatics and sequencing technology over the past 10 years. Our expertise in identifying functional biomarkers and investigating prostate cancer heterogeneity has led to key discoveries in the distinction between indolent and aggressive cancer types. Our mission is to identify potential therapeutic targets and bridge the latest in cancer genetics research with individual patient oriented clinical care. The Rubin lab is based in Bern at the Department for BioMedical Research (DBMR), University of Bern, Switzerland.
From Cancer Dependence to Cancer Therapeutics
William Sellers is a core institute member of the Broad Institute of MIT and Harvard, a faculty member at Harvard Medical School (HMS), and faculty member and senior advisor to the president for experimental therapeutics at Dana-Farber Cancer Institute (DFCI). He is a distinguished cancer scientist, with deep experience in cancer biology and cancer therapeutics.
Youtube - Lecture of Tuesday June 12, 2018